Praful Nair

Dr. Praful Nair

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Journal of Cleaner Production
Verified
Journal Article
Closed access
PNPraful Nair
Praful Nair
BSBhaskar Singh
Bhaskar Singh
SUS.N. Upadhyay
S.N. Upadhyay
YSY.C. Sharma
Y.C. Sharma

7 June 2014 in Annual Review of Chemical and Biomolecular Engineering
Verified
Journal Article
Closed access
NONúria Sancho Oltra
Núria Sancho Oltra
PNPraful Nair
Praful Nair
DDDennis E Discher
Dennis E Discher
Polymersome vesicles and wormlike filomicelles self-assembled with amphiphilic, degradable block copolymers have recently shown promise in application to cancer therapy. In the case of filomicelles, dense, hydrophilic brushes of poly(ethylene glycol) on these nanoparticles combine with flexibility to nonspecifically delay clearance by phagocytes in vivo, which has motivated the development of “self” peptides that inhibit nanoparticle clearance through specific interactions. Delayed clearance, as well as robustness of polymer assemblies, opens the dosage window for delivery of increased drug loads in the polymer assemblies and increased tumor accumulation of drug(s). Antibody-targeting and combination therapies, such as with radiotherapy, are emerging in preclinical animal models of cancer. Such efforts are expected to combine with further advances in polymer composition, structure, and protein/peptide functionalization to further enhance transport through the circulation and permeation into disease sites.

5 April 2019 in Polymers
Verified
Journal Article
Open access
PDF file
PNPraful Nair
Praful Nair
The side-effects associated with chemotherapy necessitates better delivery of chemotherapeutics to the tumor. Nanoparticles can load higher amounts of drug and improve delivery to tumors, increasing the efficacy of treatment. Polymeric nanoparticles, in particular, have been used extensively for chemotherapeutic delivery. This review describes the efforts made to deliver combination chemotherapies and inhibit oncogenic pathways using polymeric drug delivery systems. Combinations of chemotherapeutics with other drugs or small interfering RNA (siRNA) combinations have been summarized. Special attention is given to the delivery of drug combinations that involve either paclitaxel or doxorubicin, two popular chemotherapeutics in clinic. Attempts to inhibit specific pathways for oncotherapy have also been described. These include inhibition of oncogenic pathways (including those involving HER2, EGFR, MAPK, PI3K/Akt, STAT3, and HIF-1α), augmentation of apoptosis by inhibiting anti-apoptosis proteins (Bcl-2, Bcl-xL, and survivin), and targeting dysregulated pathways such as Wnt/β-catenin and Hedgehog.

9 May 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ASAlexandra Sneider
Alexandra Sneider
YLYing Liu
Ying Liu
BSBartholomew Starich
Bartholomew Starich
WDWenxuan Du
Wenxuan Du
PNPraful Nair
Praful Nair
DWDenis Wirtz
Denis Wirtz
Tissue stiffness is a critical prognostic factor in breast cancer and is associated with metastatic progression. Here we show an alternative and complementary hypothesis of tumor progression whereby physiologic matrix stiffness affects the quantity and protein cargo of small extracellular vesicles (EV) produced by cancer cells, which in turn aid cancer cell dissemination. Primary patient breast tissue released by cancer cells on matrices that model human breast tumors (25 kPa; stiff EVs) feature increased adhesion molecule presentation (ITGα2β1, ITGα6β4, ITGα6β1, CD44) compared with EVs from softer normal tissue (0.5 kPa; soft EVs), which facilitates their binding to extracellular matrix proteins including collagen IV, and a 3-fold increase in homing ability to distant organs in mice. In a zebrafish xenograft model, stiff EVs aid cancer cell dissemination. Moreover, normal, resident lung fibroblasts treated with stiff and soft EVs change their gene expression profiles to adopt a cancer-associated fibroblast phenotype. These findings show that EV quantity, cargo, and function depend heavily on the mechanical properties of the extracellular microenvironment. Significance: Here we show that the quantity, cargo, and function of breast cancer–derived EVs vary with mechanical properties of the extracellular microenvironment.

13 May 2016 in Nanomedicine
Verified
Journal Article
Closed access
PNPraful Nair
Praful Nair
SKSa Karthick
Sa Karthick
KSKyle R Spinler
Kyle R Spinler
MVMohammad R Vakili
Mohammad R Vakili
ALAfsaneh Lavasanifar
Afsaneh Lavasanifar
DDDennis E Discher
Dennis E Discher
Aim: In order to improve the delivery of aromatic drugs by micellar assemblies, and particularly by long and flexible filomicelles, aromatic groups were integrated into the hydrophobic block of a degradable diblock copolymer. Materials & methods: Aromatic filomicelles were formed by self-directed assembly of amphiphilic diblock copolymer PEG–PBCL with suitable block ratios. Worm-like filomicelles with an aromatic core were loaded with a common chemotherapeutic, Paclitaxel, for tests of release as well as effects on cancer cell lines in vitro and in vivo. Results: Aromatic filomicelles loaded more Paclitaxel than analogous aliphatic systems. Cell death and aneuploidy of surviving cells (which indicates toxicity) were highest for carcinoma lines treated in vitro with the new filomicelles. Initial tests in vivo also suggest more potent tumor shrinkage. Conclusion: Flexible filomicelles with an aromatic core form an efficient drug delivery system that leads to higher cell death than previously reported system...

15 March 2024 in Science Advances
Verified
Journal Article
Closed access
PNPraful Nair
Praful Nair
LDLudmila Danilova
Ludmila Danilova
EGEstibaliz Gómez-De-Mariscal
Estibaliz Gómez-De-Mariscal
DKDongjoo Kim
Dongjoo Kim
RFRong Fan
Rong Fan
DWDenis Wirtz
Denis Wirtz
Cell migration is a critical contributor to metastasis. Cytokine production and its role in cancer cell migration have been traditionally associated with immune cells. We find that the histone methyltransferase Mixed-Lineage Leukemia 1 (MLL1) controls 3D cell migration via cytokines, IL-6, IL-8, and TGF-β1, secreted by the cancer cells themselves. MLL1, with its scaffold protein Menin, controls actin filament assembly via the IL-6/8/pSTAT3/Arp3 axis and myosin contractility via the TGF-β1/Gli2/ROCK1/2/pMLC2 axis, which together regulate dynamic protrusion generation and 3D cell migration. MLL1 also regulates cell proliferation via mitosis-based and cell cycle–related pathways. Mice bearing orthotopic MLL1-depleted tumors exhibit decreased lung metastatic burden and longer survival. MLL1 depletion leads to lower metastatic burden even when controlling for the difference in primary tumor growth rates. Combining MLL1-Menin inhibitor with paclitaxel abrogates tumor growth and metastasis, including preexistent metastasis. These results establish MLL1 as a potent regulator of cell migration and highlight the potential of targeting MLL1 in patients with metastatic disease.